7457results about "Senses disorder" patented technology

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

The invention belongs to the field of biological medicine, and particularly relates to application of recombinant III-type humanized collagen in an injection. The invention provides an injection, the injection comprises recombinant III-type humanized collagen, the amino acid sequence of the recombinant III-type humanized collagen comprises n repetitions of the sequence as shown in SEQ ID NO.1, n is an integer greater than or equal to 1, and when n is an integer greater than or equal to 2, the repetitions are directly connected; moreover, when the injection is applied in one application period, the total application amount of the recombinant III-type humanized collagen is less than or equal to 3640 mg / kg. The recombinant III-type humanized collagen has high-dose injection safety, and can be applied in a single high-dose manner or continuously applied to realize high-dose application in a total amount level.

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention relates to the technical field of eutectic crystals, in particular to a lutein and mannitol eutectic crystal as well as a preparation method and application thereof, an XRD (X-Ray Diffraction) pattern of the eutectic crystal has characteristic diffraction peaks at least at positions where 2 theta angles are 9.71 degrees, 19.44 degrees, 20.4 degrees, 21.17 degrees, 22.07 degrees, 24.67 degrees, 25.32 degrees, 36.1 degrees, 40.39 degrees and 44.9 degrees, and error tolerance of + / -0.2 degrees exists; a characteristic endothermic peak exists at 163.7 DEG C in a DSC spectrum, and an error tolerance of + / -0.2 DEG C exists; the preparation method comprises the following steps: respectively dissolving mannitol and xanthophyll in water and absolute ethyl alcohol, mixing, carrying out high-temperature and high-pressure reaction, standing, crystallizing, filtering, spray-drying and grinding to obtain the eutectic crystal, and the eutectic crystal can be applied to cosmetics, health-care products, foods and medicines. The eutectic crystal provided by the invention has the advantage of good stability.

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes. In some embodiments, a provided compound is a compound of Formula I,or a pharmaceutically acceptable salt thereof. In some embodiments, a provided method is a method of alleviating or abating a disorder or disease associated with aldosterone synthase (CYP11B2) or ameliorating a symptom thereof.

The invention discloses a xanthophyll-nicotinamide eutectic crystal and a preparation method and application thereof, the eutectic crystal is formed by xanthophyll and nicotinamide according to the molar ratio of 1: 1 through intermolecular interaction of hydrogen bonds, Van der Waals force and the like, and the molecular formula is C46H62N2O3. According to the invention, xanthophyll and nicotinamide are combined through a co-crystal technology, a novel co-crystal with good water solubility and high bioavailability is formed, and the solubility and absorption efficiency of xanthophyll are significantly improved.

To provide an oral composition for effectively activating plasmacytoid dendritic cells (pDCs).SOLUTION: An oral composition for activating plasmacytoid dendritic cells (pDCs), comprising Lacticaseibacillus rhamnosus CRL1505, wherein the composition is preferably intended for immune activation. The oral composition for activating pDCs is considered to: regulate both innate immunity and acquired immunity; act on an overall immune function, maintain a normal immune function, and maintain good physical conditions. The present invention also provides an oral composition for immune activation characterised in that it comprises Lacticaseibacillus rhamnosus CRL1505, wherein the immune activation is intended for symptoms such as nasal congestion.SELECTED DRAWING: Figure 1

The invention discloses a cationic lipid compound, a lipid carrier containing the same and application, and belongs to the technical field of gene therapy. The cationic lipid compound disclosed by the invention has a structure as shown in a formula I, or an isomer, a pharmaceutically acceptable salt and a prodrug thereof. The lipid nanoparticles have the advantages of stable nanostructure, uniform size distribution, good biological biocompatibility, high in-vivo and in-vitro mRNA delivery efficiency, selective organ targeting and the like. The cationic lipid reaction operation is simple, the raw materials are cheap and easy to obtain, and the cationic lipid has high safety, is beneficial to industrial production and quality control, and has a good application prospect.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The present invention provides a novel therapeutic drug for treating a Prom1-associated retinal disease. Specifically, the present invention provides an optimized Prom1 gene expression cassette, an rAAV viral vector, and a gene therapy drug. The drug of the present invention can specifically express the PROM1 protein in the retinal photoreceptor layer, and is suitable for the clinical treatment of a retinal disease associated with Prom1 gene mutation.

An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The invention relates to a near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system and a preparation method and application thereof, a mesoporous silicon coated up-conversion nano-carrier and an efficient photosensitizer are compounded to form a photo-response core unit, and then the photo-response core unit is intelligently integrated with photo-curing hydrogel to form the near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system. The general problem of aggregation and quenching of photosensitive molecules is relieved by utilizing the unique space confinement effect of the mesoporous structure, the ICG photo-thermal efficiency and photodynamic performance are enhanced, under precise excitation of a near-infrared light source, the system can activate a photo-crosslinking reaction through an up-conversion luminescence process, in-situ conversion from a liquid eye drop preparation to a stable gel state is achieved, and the stability of the eye drop preparation is improved. A lasting drug reservoir is formed on the surface of the cornea; synchronously excited photodynamic and photo-thermal dual-mode treatment generates a remarkable synergistic antibacterial effect, and shows an excellent removal capability on pathogens including highly drug-resistant bacteria; meanwhile, an ideal microenvironment is created for tissue repair through high biocompatibility and a stable mechanical matrix, and integrity recovery of cornea structures and functions is promoted.

The present invention relates to compounds of formula (I), their synthesis and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders. [Formula 1] TIFF2023523300000191.tif51156

The invention belongs to the technical field of medicines, and particularly relates to a multi-effect composition containing ergothioneine, a preparation method of the multi-effect composition and application of the multi-effect composition in eye products. The multi-effect composition is prepared from ergothioneine, tromethamine and sodium hyaluronate according to the mass ratio of (0.5 to 10) to (1 to 5) to (0.5 to 3). According to the multi-effect composition containing the ergothioneine, the tromethamine in the composition can protect the stability of the ergothioneine under the conditions of illumination and high temperature; the ergosulfide can protect the activity of macromolecular sodium hyaluronate. The synergistic compatibility of the ergothioneine, the sodium hyaluronate and the tromethamine is utilized, so that the moisturizing effect and the eye protection effect of the composition can be remarkably improved. The ergothioneine-containing multi-effect composition provided by the invention has the effect of preventing cataract through specific components and proportions, and has the advantages of long-acting eye moistening and good stability.

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

Disclosed are compounds, pharmaceutical compositions and uses thereof as complement factor D inhibitors, specifically a compound represented by formula (I), its tautomers, its stereoisomers, its prodrugs, or any one of the foregoing pharmaceutically acceptable salts, or any one of the foregoing solvates, wherein the compound has excellent inhibitory activity against complement factor D and has excellent pharmacokinetic and pharmacodynamic activity. JPEG2024533782000131.jpg47170

The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.

The invention discloses granules of a composition containing rhizoma polygonati. The granules comprise the following components in percentage by weight: 30%-50% of composition dry paste powder, 38%-58% of a filling agent, 0.1%-20% of an adhesive and 0.1%-2% of a flow aid, the composition comprises rhizoma polygonati, fructus lycii, flos chrysanthemi and radix glehniae. Wherein the filling agent is dextrin; wherein the adhesive is maltodextrin or povidone; wherein the flow aid is colloidal silicon dioxide. According to the composition disclosed by the invention, proper auxiliary materials and an adding mode thereof are selected, so that the inherent properties of the original extract are improved, the extract is not easy to soften, the caking tendency caused by moisture absorption or heat absorption among particles is avoided, and the caking probability is reduced.

The invention relates to the technical field of medicines, in particular to application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating myopia. The invention provides application of alpha-ketoglutaric acid or pharmaceutically acceptable salt thereof in preparation of products for preventing and / or treating myopia, and the alpha-ketoglutaric acid is taken as an important intermediate metabolite of tricarboxylic acid cycle in mitochondrial aerobic respiration and has oral safety; researches show that alpha-ketoglutaric acid can inhibit myopia progress and ocular axis elongation by improving sclera fibroblast phenotype transformation and extracellular matrix remodeling, and a new idea is provided for preparation of myopia intervention drugs.